CoChat

Treatment of sarcopenia: the road to the future

Open access
Morley, John E. · 2018 · Journal of Cachexia, Sarcopenia and Muscle
Cited by 70

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

This year, two new consensus conferences on the diagnosis and management of sarcopenia have been published.1, 2 Both confirm the need to screen for sarcopenia in older persons. Suggested screening approaches are the SARC-F,3, 4 the Ishii screening test,5, 6 or grip strength. It should be recognized that grip strength was suggested for screening by one consensus group1 and as part of the diagnosis by the other.2 Measuring mid-calf muscle circumference improves the sensitivity and specificity of the SARC-F when it is compared with the consensus definitions.7-9 A number of consensus definitions for sarcopenia have been developed.2, 11-13 All require either functional impairment (slow walking speed) or grip strength together with a low muscle mass. While the persons diagnosed by any of these definitions overlap, they all have different sensitivity and specificity when compared with one another or functional outcomes due to the different cut-off points.14, 15 The Asian Group made it clear that cut-offs are very different for persons with Asian ethnicity compared with Europeans.13 [These definitions have led to the International Classification of Disease (10th edition) to recognize sarcopenia as an independent condition (M62.84)].16, 17 There are a number of different methods available to measure lean body mass including air displacement plethysmography, bioelectrical impedance analyses, dual-energy X-ray absorptiometry, and ultrasound.18-21 Each of these methods has been demonstrated to have problems in accurately determining muscle mass.22 Recently, D3-creatine dilution has been demonstrated to be more accurate in measuring muscle mass23 and more strongly related to physical performance.22 While age-related sarcopenia is considered to be primary sarcopenia, a number of disease states, for example, diabetes mellitus,24, 25 male hypogonadism,26, 27 and chronic obstructive pulmonary disease28 can produce secondary sarcopenia. Cachexia is a complex metabolism disorder leading to anorexia, muscle wasting, and loss of fat.29 The Glasgow Prognostic Score (low serum albumin and elevated C-reactive protein) can be used to distinguish secondary sarcopenia from cachexia.30 The advent of patient-centred (P4) care has increased attention to the fact that different molecular changes can result in the need to have different therapeutic approaches to similar conditions such as sarcopenia31, 32 (Table 1). In this issue of the journal, Riuzzi et al.33 highlight that sarcopenia can result from a variety of molecular changes resulting in changes in myofibre metabolism and alterations in satellite cell properties. Abnormalities in these pathways can be due to insulin growth factor-1/insulin receptors, activin (myostatin) receptors, tropomysin receptor, kinase C receptors (neurotrophin and G-protein receptors), a variety of cytokines, and testosterone through activation of β-catenin.34-38 Thus, in the long run, the ideal treatment of sarcopenia will involve identification of the aberrant molecular pathway and the possible hormone causing this imbalance. At present, the treatment of sarcopenia is focused on resistance exercise.1 The use of leucine essential amino acids and/or β-hydroxybutyrate has not been clearly established but would seem a reasonable adjunct in persons with low protein intake.39-45 Drugs that have potential to treat sarcopenia include testosterone and anabolic steroids,46-48 myostatin antibodies,49, 50 activin receptor antibodies,51 and the ghrelin agonist, anamorelin.52 There is also interest in the role of beta-blockade,53 some angiotensin-converting enzyme inhibitors,54 and sarconeos, which activates the MAS (angiotensin-1) receptor.55 A recent study suggested that metformin may improve mobility in persons with diabetes mellitus.56 Still highly experimental but likely to play a role in the future management of sarcopenia are CRISPR techniques57 and possibly stem cell therapy.58 Sarcopenia is a major cause of physical frailty59-61 and falls62, 63 in older persons. As at present, there is a simple therapy—aggressive resistance exercise—when sarcopenia is detected early, it seems reasonable to screen older persons and those with diabetes for sarcopenia and frailty using the Rapid Geriatric Assessment tool64-67 and begin secondary prevention as early as possible. The SarQOL can be utilized to measure an improvement of health-related quality of life in these persons.68 A recent study demonstrated that an intense level of physical exercise in hospital patients can prevent the muscle and functional loss that occurs in hospitalized patients.69 The author certifies that he complies with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.70 None declared.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcsm.12386

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 70

Metadata

Authors
Morley, J. E.
Venue
Journal of Cachexia, Sarcopenia and Muscle
Publisher
Wiley
Published
2018-12
Volume
9
Issue
7
Pages
1196-1199
ISSN
  • 2190-5991 (ISSN-L)
  • 2190-6009
OpenAlex
W2912282082
Cited by
70
References
25
FWCI
6.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.